TransMedics Group Inc (TMDX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
TransMedics Group Inc (TMDX) Stock Forecast
Analysts expect TransMedics Group (TMDX) to earn $1.67 per share in the fiscal year ending Dec 31, 2026, on revenue of $767.14M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 23.1% |
| Buy | 6 | 46.2% |
| Hold | 4 | 30.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 49.1% and revenue estimates rise 17.5%.
- Fiscal year ending Dec 31, 2026
- $1.67
- EPS consensus, revenue $767.14M
- Fiscal year ending Dec 31, 2027
- $2.49
- EPS consensus, revenue $901.36M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.67 | $1.51 to $1.78 | 10 | $767.14M | $742.00M to $772.20M | 12 |
| Dec 31, 2027 | $2.49 | $2.00 to $3.11 | 10 | $901.36M | $867.00M to $949.00M | 12 |
Quarterly Estimates
The EPS consensus is $0.46 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.46 | $0.33 to $0.56 | 14 | $205.69M | $186.10M to $215.57M | 13 |
| Mar 31, 2027 | $0.46 | $0.35 to $0.53 | 4 | $212.29M | $206.20M to $221.86M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 8 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.1% from $1.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.67 | $1.51 | $1.51 | $1.54 | $1.56 | +7.1% |
| Fiscal year ending Dec 31, 2027 | $2.49 | $2.25 | $2.25 | $2.31 | $2.31 | +7.8% |
| Quarter ending Mar 31, 2027 | $0.46 | $0.46 | $0.46 | $0.48 | $0.48 | -2.5% |
Frequently Asked Questions About TMDX
What is the TMDX stock forecast?
Consensus analyst estimates put TransMedics Group's EPS at $1.67 for the fiscal year ending Dec 31, 2026, on revenue of $767.14M. The consensus rating from 13 analysts is Buy.
How do analysts rate TMDX stock?
Of 13 analysts covering TransMedics Group, 3 rate it Strong Buy, 6 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TMDX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.67, with estimates from $1.51 to $1.78 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.49, with estimates from $2.00 to $3.11 from 10 analysts.
What revenue do analysts expect from TransMedics Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $767.14M, with estimates from $742.00M to $772.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $901.36M, with estimates from $867.00M to $949.00M.
How many analysts cover TMDX?
13 analysts rate TransMedics Group stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TMDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors